Related references
Note: Only part of the references are listed.BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
W. T. Parker et al.
BRITISH JOURNAL OF CANCER (2013)
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis
James D. Griffin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F. J. Giles et al.
LEUKEMIA (2013)
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
F. U. Woehrle et al.
LEUKEMIA (2013)
Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
Aylin Camgoz et al.
LEUKEMIA & LYMPHOMA (2013)
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
Roel Polak et al.
BLOOD (2012)
GAB2-a Scaffolding Protein in Cancer
Sarah J. Adams et al.
MOLECULAR CANCER RESEARCH (2012)
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Alberto M. Martelli et al.
ONCOTARGET (2012)
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Chintda Santiskulvong et al.
CLINICAL CANCER RESEARCH (2011)
The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia
Konrad Aumann et al.
HUMAN PATHOLOGY (2011)
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Maria C. Manara et al.
CLINICAL CANCER RESEARCH (2010)
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
James J. Manfredi
GENES & DEVELOPMENT (2010)
Regulation of XIAP Translation and Induction by MDM2 following Irradiation
Lubing Gu et al.
CANCER CELL (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Romina Marone et al.
MOLECULAR CANCER RESEARCH (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Francois-Xavier Mahon et al.
CANCER RESEARCH (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
L. Gu et al.
LEUKEMIA (2008)
Targeted inactivation of mdm2 RING finger e3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation
Koji Itahana et al.
CANCER CELL (2007)
Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells
Ian R. Logan et al.
PROSTATE (2007)
Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells
A. VanderBorght et al.
ONCOGENE (2006)
MTOR, translation initiation and cancer
Y. Mamane et al.
ONCOGENE (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)
M Scherr et al.
BLOOD (2006)
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia
PW Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
RAS and RHO GTPases in G1-phase cell-cycle regulation
ML Coleman et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation
JH Feng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases
PW Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
Critical role for Gab2 in transformation by BCR/ABL
M Sattler et al.
CANCER CELL (2002)
Share Paper
